XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Out-Licensing Agreements (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 02, 2022
USD ($)
item
Feb. 21, 2022
USD ($)
item
agreement
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Collaborative agreements            
Product revenue, net     $ 99,135 $ 12,095 $ 158,296 $ 19,799
License and collaboration revenue            
Collaborative agreements            
Product revenue, net     $ 65,711   75,711  
Collaboration Agreements | Huadong rilonacept            
Collaborative agreements            
Notice period to terminate the agreement   12 months        
Collaboration Agreements | Huadong rilonacept            
Collaborative agreements            
Number of agreements entered into | agreement   2        
Upfront payments received   $ 22,000        
Term of agreement for royalty payments   12 years        
Notice period to terminate the agreement if there is no material development or commercialization activities with respect to the licensed product in China   60 days        
Collaboration Agreements | Huadong rilonacept | Minimum            
Collaborative agreements            
Time period threshold of continuous material development or commercialization activities in China that, if not met, can trigger the right for the Company to terminate the agreement   6 months        
Territory License - Rilonacept | Huadong rilonacept            
Collaborative agreements            
Upfront payments received   $ 12,000        
Number of performance obligations in an agreement | item   1        
Transaction price         12,000  
Territory License - Rilonacept | Huadong rilonacept | Maximum            
Collaborative agreements            
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones   $ 70        
Territory License - Mavrilimumab | License and collaboration revenue            
Collaborative agreements            
Product revenue, net         10,000  
Territory License - Mavrilimumab | Huadong rilonacept            
Collaborative agreements            
Upfront payments received   $ 10,000        
Number of performance obligations in an agreement | item   2        
Transaction price         10,000  
Territory License - Mavrilimumab | Huadong rilonacept | Maximum            
Collaborative agreements            
Payments to be received by the company upon the achievement of specified development, regulatory and sales milestones   $ 576        
Worldwide License - Vixarelimab | Genentech            
Collaborative agreements            
Upfront payments received $ 80,000          
Payments to be received by the company upon delivery of certain materials 20,000          
Milestone receipts $ 600,000          
Number of performance obligations in an agreement | item 4          
Product revenue, net         $ 65,711  
Transaction price $ 80,000